NCT04938414 is a clinical trial of Lumbar puncture in Subarachnoid Hemorrhage, Aneurysmal, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04938414?

NCT04938414 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT04938414?

Interventions in NCT04938414: Lumbar puncture.

What condition does NCT04938414 study?

NCT04938414 studies Subarachnoid Hemorrhage, Aneurysmal.

Is NCT04938414 still recruiting?

NCT04938414 is currently completed. Last updated 6 January 2022.

Last reviewed 2022-01-06 · How we verify

NCT04938414

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigate the Relationship Between Inflammatory and Coagulation in SAH CSF

Completed Last updated 6 January 2022

What this trial tests

trial testing Lumbar puncture in Subarachnoid Hemorrhage, Aneurysmal in 40 participants. Completed in 1 October 2021.

Timeline

1 December 2020

Primary endpoint
1 August 2021

1 October 2021

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	1 December 2020
Primary completion	1 August 2021
Estimated completion	1 October 2021
Sites	1 location across China

Drugs / interventions tested

Lumbar puncture — full drug profile →

Conditions studied

Subarachnoid Hemorrhage, Aneurysmal — all drugs for Subarachnoid Hemorrhage, Aneurysmal →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 30 to 80, any sex, with Subarachnoid Hemorrhage, Aneurysmal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigate the role of inflammasome and blood coagulation response in human cerebrospinal fluid after subarachnoid hemorrhage.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Inhibition of caspase-1-mediated inflammasome activation reduced blood coagulation in cerebrospinal fluid after subarachnoid haemorrhage.
Fang Y, Wang X, Lu J, Shi H, et al · · 2022 · cited 49× · PMID 35101655 · DOI 10.1016/j.ebiom.2022.103843
Single-Cell RNA Sequencing and Spatial Transcriptomics Reveal Pathogenesis of Meningeal Lymphatic Dysfunction after Experimental Subarachnoid Hemorrhage.
Wang X, Zhang A, Yu Q, Wang Z, et al · · 2023 · cited 36× · PMID 37211686 · DOI 10.1002/advs.202301428
Adenosine triphosphate induced cell death: Mechanisms and implications in cancer biology and therapy.
Zhang HL, Sandai D, Zhang ZW, Song ZJ, et al · · 2023 · cited 11× · PMID 38179405 · DOI 10.5306/wjco.v14.i12.549

Verify or expand the search:

Other trials of Lumbar puncture

Trials testing the same drug.

NCT06353412 — Current Treatment Methods of Idiopathic Intracranial Hypertension · not yet recruiting
NCT05399602 — The Role of Neurofilament Light (NfL) in Patients With Hydrocephalus · NA · completed
NCT06083233 — Role of Brain Specific Biomarkers in Hydrocephalus · completed
NCT05806697 — Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study · NA · recruiting
NCT05516732 — Serotonin Release in Premotor and Motor PD · recruiting

Other recruiting trials for Subarachnoid Hemorrhage, Aneurysmal

Currently open trials in the same condition.

NCT04696523 — Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage · Phase 2 · recruiting
NCT06819657 — Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid H · NA · recruiting
NCT06766422 — AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction · recruiting
NCT06906432 — Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage · recruiting
NCT06218654 — Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04938414 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 6 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04938414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing